Showing results (391-400 of 824) with videos related to

Sort By:
Pageof 83
Kidney360|November 10, 2025
The Association of Kidney Function on Survival in Patients with AL Amyloidosis after Autologous Stem Cell Transplantation: A Multicenter StudyUmut Selamet, Kole Joachim, Heather Lin, et al.
Ejhaem|August 21, 2023
Selinexor: Targeting a novel pathway in multiple myelomaClifton C Mo, Andrew J Yee, Shonali Midha, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|April 5, 2026
Assessment of Cardiac Involvement in Rare Forms of Amyloidosis Using PET/CT with 124I-Evuzamitide (124I-p5+14, AT-01)Olivier F Clerc, Ardel J Romero Pabón, Sarah A M Cuddy, et al.
International Journal of Cancer|December 13, 2007
Risks of cancer among a cohort of 23,935 men and women with osteoporosisKatherine A McGlynn, Gloria Gridley, Lene Mellemkjaer, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation studyPaul G Richardson, Asher A Chanan-Khan, Melissa Alsina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple MyelomaXiaoyan Feng, Li Zhang, Chirag Acharya, et al.
Cancer Letters|February 28, 2002
Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitorsMasaharu Akiyama, Osamu Yamada, Naotoshi Kanda, et al.
Nature Reviews. Disease Primers|July 21, 2017
Multiple myelomaShaji K Kumar, Vincent Rajkumar, Robert A Kyle, et al.
Future Oncology (London, England)|December 23, 2017
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study designPaul G Richardson, Michel Attal, Frank Campana, et al.
Pageof 83